Learn peptides step by step

2025 Peptide Therapy Review: Why Human Data Still Lags the Hype

A 2025 review makes the same point the peptide world keeps avoiding: some compounds have real human data, and many popular names still do not.

SafetyIntermediate

BPC-157's Regulatory Momentum Is Changing How People Read the Evidence

The regulatory story matters because it changes what you can trust, what you should track, and why supply chain quality now sits beside mechanism in the BPC-157 debate.

The GH-IGF1 Axis Still Explains the Best Peptide Performance Stories

The GH-IGF1 axis keeps showing up in peptide medicine because it links visceral fat, recovery, and lean mass. The trick is separating the clinical signal from the wellness noise.

BPC-157 Safety in 2026: What the Evidence Actually Says About Recovery and Risk

BPC-157 has a real research footprint, but most of the confidence in the compound still comes from preclinical work. That gap matters when people start talking about safety like the answer is settled.

SafetyIntermediate

BPC-157 and TB-500 for Pet Recovery: What Dog and Cat Owners Should Know

Pet owners are hearing more about BPC-157 and TB-500 for recovery. This guide separates the real biology from the social-media hype and shows what actually matters for healing.

Regeneration or Risk? What the New BPC-157 Review Says About Musculoskeletal Healing

The new BPC-157 review is useful because it separates mechanism from marketing. The peptide looks biologically interesting, but the human evidence is still thin.

FDA Peptide Compounding Review: What the Seven-Peptide Debate Means for Buyers and Clinics

Regulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.

Therapeutic Peptides in Gerontology: What Healthy Aging Research Actually Shows

Healthy aging is not a slogan. It is a measurable question about inflammation, tissue repair, metabolic control, and whether a peptide has human data behind it.

Therapeutic Peptides in Orthopaedics: What the New Review Actually Means for Injury Recovery

Orthopaedics is paying closer attention to peptides because the field keeps running into the same problem: recovery is biology, but biology still needs evidence before it becomes a protocol.

Injectable Peptides in Sports Medicine: What the Evidence and Antidoping Rules Actually Say

Sports medicine keeps pulling peptides into the conversation because recovery pressure is real. The hard part is separating promising biology from weak evidence, gray-market hype, and antidoping risk.

What Real-World GLP-1 Data Actually Tells Us About Safety and Results

Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.

MOTS-c and Cardiac Ischemia-Reperfusion: What the New Rat-Heart Study Shows

MOTS-c is showing up in cardiac stress research. A new rat-heart study points toward mitochondrial bioenergetics, mtDNA integrity, and post-ischemic recovery.

MOTS-c and Soft Tissue Survival: What the New Autophagy Study Suggests

MOTS-c is being studied beyond energy and metabolism. New research points toward tissue-stress biology, lysosomal stability, and cell survival under ischemic pressure.

GLP-1s and Breast Cancer Risk: What the New Signal Means

GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.

Peptide Clinical Evidence in 2026: How to Separate Signal from Hype

Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.

BPC-157 and Ischemia-Reperfusion Injury: What the 2026 Rat Study Found

New 2026 data puts BPC-157 into a sharper recovery frame: oxidative stress, inflammation, apoptosis, angiogenesis, and the limits of animal evidence.

GLP-1s and Macular Degeneration: What the Eye Studies Say

GLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.

GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says

GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.

Peptide Regulation and Sourcing Safety in 2026

The biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.

BPC-157 and GLP-1 Side Effects: What the Research Really Shows

GLP-1 receptor agonists cause nausea in up to 44% of users and it is the top reason for discontinuation. Here is what the research shows about BPC-157 as a potential gut protectant, and where the evidence stops.

Injectable Peptide Safety Checklist: What Doctors Want Patients to Know in 2026

AMA and FDA updates make one thing clear: peptide interest is moving faster than human evidence, dosing standards, and product-quality controls. Use this checklist before trusting a vial.

ProtocolsIntermediate

Viral Peptide Stack Transformations: How to Read the Evidence

Stack stories spread fast because they are visual and emotional. The smarter move is not to copy the protocol. It is to ask better evidence questions.

BPC-157 Human Hamstring Trial: Why This Study Matters

BPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.

Wellness Peptides and the Evidence Gap: What ECRI and ISMP Warned

A new ECRI and ISMP warning says popular wellness peptides are being marketed faster than the evidence can support. Here is how to separate compound science from product risk.

Peptide Therapy for Sports Injuries: What 2026 Evidence Really Shows

A new sports medicine review puts injury-recovery peptides in context. Some mechanisms are promising, but human evidence, safety data, and regulatory status still matter.

GLP-1 Food Noise: Why It Comes Back After Stopping and What Actually Helps

Food noise — that constant mental chatter about food — often comes back after stopping GLP-1 peptides. Here's the science of why, and what actually helps: maintenance strategies, stacking options, and realistic expectations.

Peptides for Psoriasis and Autoimmune Skin Conditions: What the Research Shows

Psoriasis affects 125 million people worldwide. While peptides aren't a cure, emerging research suggests certain compounds may help calm inflammation and support skin repair. Here's what the science says.

ProtocolsIntermediate

BPC-157 and TB-500 for Disc Herniation Recovery: A Complete Protocol Guide

BPC-157 and TB-500 are the two most evidence-backed peptides for structural tissue repair. For herniated disc recovery, they work through complementary pathways — here's how to stack them, dose them, and phase in the rest of a recovery protocol.

ProtocolsIntermediate

IGF-1 LR3 vs HGH: Dosing, Use Cases, and Safety Monitoring

IGF-1 LR3 and HGH are often grouped together, but they act at different points in the GH/IGF-1 axis. Here is the protocol-level breakdown for clinicians, athletes, and longevity-focused users.

11m

BPC-157: The Peptide That Regenerates Tissue—Science, Clinical Evidence, and Real Results

BPC-157 activates multiple tissue repair pathways simultaneously. Users report faster recovery from injury, improved gut healing, enhanced joint mobility—backed by published clinical data.

BPC-157 and Wound Healing: The Science Behind the 'Body Protection Compound'

BPC-157 accelerates tissue repair by stimulating angiogenesis and collagen synthesis. Here's what the research shows and what users need to know.

12m

BPC-157: The Tendon Recovery Peptide Backed by Clinical Research

BPC-157 shows promise in clinical research for accelerating tendon repair and recovery. Learn how this peptide works and what the science says about its efficacy.

12m

GLP-1 Agonists for Metabolic Health: Clinical Evidence & Body Recomposition Strategy

GLP-1 agonists have revolutionized metabolic health. Learn how these peptides work, their effects on metabolism, and how to use them strategically for body composition goals.